agilon Swings to $35M Profit, Lifts Full-Year EBITDA Outlook to $145-155M
AGL has more than doubled off its 52-week low of $7.48.
Summary
agilon flipped to a $35 million net profit in Q3 2026 from a $110 million loss a year earlier, and Adjusted EBITDA came in at $64 million versus negative $91 million. Revenue rose 6% to $1.52 billion on better-than-expected burden of illness performance and improved payor contracting. The medical services expense ratio dropped to 88.5% from 104.0%, though the company notes that includes favorable claims development from the first half of 2026. Management raised full-year 2026 Adjusted EBITDA guidance to $145-$155 million from $75-$95 million, a big step up, while nudging revenue guidance to $5.87-$5.89 billion. Membership keeps shrinking — total members on the platform fell 8% to 566,000 as the company exits markets and contracts for profitability — so the profit improvement is coming from cost and pricing, not growth. Balance sheet shows $312 million of cash and marketable securities against $32 million of total debt.
At the time of this announcement, AGL was trading at $96.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $7.48 to $133.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.